These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15479373)

  • 1. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulation factors with improved properties for hemophilia gene therapy.
    Pipe SW
    Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia.
    Miller G; Steinbrecher RA; Murdock PJ; Tuddenham EG; Lee CA; Pasi KJ; Goldspink G
    Gene Ther; 1995 Dec; 2(10):736-42. PubMed ID: 8750013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for hemophilia A.
    Connelly S; Kaleko M
    Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime.
    Scheiflinger F; Dorner F
    Wien Klin Wochenschr; 1999 Mar; 111(5):172-80. PubMed ID: 10226347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-factor VIII antibodies: a 2005 update.
    Lavigne-Lissalde G; Schved JF; Granier C; Villard S
    Thromb Haemost; 2005 Oct; 94(4):760-9. PubMed ID: 16270627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
    Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
    Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hemophilias--gene therapy to come?
    Vajó Z; Sréter L
    Acta Physiol Hung; 1996; 84(2):191-8. PubMed ID: 9046365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel products for haemostasis - current status.
    Oldenburg J; Albert T
    Haemophilia; 2014 May; 20 Suppl 4():23-8. PubMed ID: 24762271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah MK; Vandendriessche T
    Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.